Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969875 | 0.71 | — | — | |
| SCHEMBL27745714 | 0.65 | RAB9A (0.44) | NOS2 | |
| SCHEMBL1894555 | 0.64 | — | — | |
| SCHEMBL16541068 | 0.64 | — | — | |
| SCHEMBL972760 | 0.60 | — | — | |
| SCHEMBL14042504 | 0.60 | CCR1 (0.44) | NOS2 | |
| SCHEMBL19910609 | 0.58 | KDM4E (0.39) | NOS2 | |
| SCHEMBL1515017 | 0.58 | — | — | |
| SCHEMBL1515119 | 0.58 | — | — | |
| SCHEMBL1515054 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2582706-A1 | 3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8178689-B2 | Tricyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | SARABU RAMAKANTH (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011157682-A1 | 3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| US-20030055251-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-03-20 | — | — | US | disclosed |
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | MSD K.K. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | NPY1R, GPR119, NPY2R | NOS2 1074/4885 |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | NOS2 309/4885 |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | NOS2 1853/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | NOS2 1853/4885 |
| US-20030055251-A1 | Novel spiro compounds | NPY1R, GPR119, OPRK1 | NOS2 352/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | NOS2 1155/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | NOS2 284/4885 |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | GPR119, PC, GOT2 | NOS2 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.